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Summary 
Complement receptor 1 (CR1) is present on erythrocytes (E-CR1), various leucocytes, and renal 
glomerular epithelial cells (podocytes). In addition, plasma contains a soluble form of CR1 (sCR1) 
By using a specific ELISA, CR1 was detected in the urine (uCR1) of normal individuals (excretion 
rate in 12 subjects, 3.12  +  1.15 #g/24 h). Contrary to sCR1, uCR1 was pelleted by centrifugation 
at 200,000 g  for 60 min. Analysis by sucrose density gradient ultracentrifugation showed that 
uCR1 was sedimenting in fractions larger than 19 S, whereas sCR1 was found as expected in 
fractions smaller than 19 S. The addition of detergents reduced the apparent size of uCR1  to 
that of sCR1.  After gel filtration on Sephacryl-300 of normal urine,  the fractions containing 
uCR1 were found to be enriched in cholesterol and phospholipids.  The membrane-association 
of uCR1 was demonstrated by analyzing immunoafhnity purified uCR1 by electron microscopy 
which revealed membrane-bound vesicles. The apparent molecular mass of uCR1  was 15 kD 
larger than E-Clkl and sCR1 when assessed by SDS-PAGE and immunoblotting. This difference 
in size could not be explained on the basis of glycosylation only, since pretreatment with N-gly- 
cosidase F reduced the size of all forms of CR1;  however, the difference in regular molecular 
mass was not abrogated. The structural alleles described for E-CR1 were also found for uCR1. 
The urine of patients who had undergone renal transplantation contained alleles of uCR1 which 
were discordant with E-CR1 in 7 of 11 individuals, indicating that uCR1 originated from the 
kidney, uCR1 was shown to bind C3b-coated immune complexes, suggesting that the function 
of CR1 was not destroyed in urine. A decrease in uCR1 excretion was observed in 3 of 10 patients 
with systemic lupus erythematosus, corresponding to the three who had severe proliferative nephritis, 
and in three of three patients with focal sclerosis, but not in six other patients with proteinuria. 
Taken together, these data suggest that glomerular podocytes release CRl-coated vesicles into 
the urine. The function of this release remains to be defined, but it may be used as a marker 
for podocyte injury. 
C 
R1 (CD35, C3b/C4b receptor) is a transmembrane pro- 
tein expressed on several circulating cells including E, 
PMN, monocytes, B-lymphocytes, and some T-lymphocytes 
(1, 2). Some specific epithelial cells have been reported to ex- 
press  CR1  as well (3,  4).  In particular CR1  is present on 
renal glomerular epithelial cells  (podocytes) (4,  5).  These 
receptors were initially identified by the adherence of C3b- 
coated sheep E and bacteria to glomeruli in frozen sections 
of human kidney (6, 7). Using immunoelectron microscopy, 
Kazatchkine et al.  (4) have shown that in glomeruli, CR1 
antigenic determinants were localized only on podocytes. More 
recently, Fischer et al. (5) demonstrated that podocyte CR1 
shares the functional, antigenic, and biochemical properties 
of E-CR1, and estimated that each podocyte bears ~200,000 
CR1. The biological function of CR1 on podocytes remains 
speculative.  It has been suggested that the presence of CR.1 
on podocytes might be necessary for the inactivation of C3b 
in a compartment (primitive urine) which is devoid of com- 
plement inhibitors (5). Except for cells derived from the cir- 
culation, no other normal renal cell in the kidney produces 
or expresses  CR1  (8,  9).  Thus,  CR1  can be considered as 
a specific marker for podocytes in the kidney. A loss of CR1 
antigen on podocytes has been found in different nephropa- 
thies such as severe proliferative nephritis of SLE, focal scle- 
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patterns  of staining  were also found in amyloidosis and in 
diabetic  nephropathy  (4). 
CR1 is also found in plasma as a soluble protein (sCR.1) 1 
whose function and size are indistinguishable  from E-CR.1 
(14).  sCR.1 might  originate  from the various cells that ex- 
press CR1 as suggested by the recent observation that PMN, 
lymphocytes, and monocytes release soluble CR1 in vitro (15). 
The concentration of plasma sCR1 in normal individuals is 
34 ng/ml.  Elevated levels were found in patients with renal 
failure and  the  concentration  of sCR1  returned  to normal 
after successful renal transplantation suggesting that the kidney 
might be, in part, responsible for the catabolism of sCR1 (15). 
This study was undertaken to determine whether CR1 is 
present in urine,  and if so, whether it originates from renal 
podocytes, from circulating cells, or from the glomerular filtra- 
tion  of sCR1. 
Materials and Methods 
Determination of CR1 in Plasma (sCR1),  Urine (uCRI), and on E 
(E-CRI).  The concentrations ofuCR1 were determined by using 
an ELISA previously described for measuring sCR1 (15). In brief, 
a mAb (3D9) against CR1 was coated on the wells. After incuba- 
tion of the sample to be tested, the CR1 bound to the first mAb 
was revealed with a biotinylated second mAb (J3D3) recognizing 
another epitope of CR1. Recombinant soluble human CR1 (r-CR1, 
kindly provided by Smith Kline Beecham Pharmaceuticals, King 
of Prussia,  PA) was used as a standard. For uCR1 determinations, 
fresh urine was centrifuged at 1,500 g for 15 min at room tempera- 
ture and samples of 10-50 gl were applied to the mAb (3D9)-coated 
wells in a final vol of 100/~1 of PBS-Tween 0.05%. The assay was 
then performed as for sCR1. The stability of urine samples was 
tested by keeping them at 4~  or room temperature for various 
periods of time before performing the ELISA. Urine samples were 
also ultracentrifuged for 60 min at 50,000 and 200,000 g before 
being tested. E-CR1 numbers were determined by direct binding 
of radiolabeled 3D9 mAb to E as previously described (16). 
Analysis of Urine by Uhracentrifugation on Sucrose Density Gradients 
(SDGU) and Gel Filtration.  Fresh urine samples were centrifuged 
at 1,500 g for 15 rain at room temperature and concentrated 10- 
fold using a PM30 (43 mm) membrane with a cut-off of 30 kD 
(Amicon, Grace SA, Walliselen ZH, Switzerland). Samples of 200 
gl of concentrated urine were layered onto 5-ml linear sucrose den- 
sity gradients  (10-50% wt/wt) (17). The gradients were centrifuged 
for 120 min at 200,000 g  at room temperature, and 24 fractions 
of 200 gl were collected from the bottom. CR1 was measured in 
the fractions using the ELISA described above. Several controls were 
included.  (a) 100 gl of human plasma which had been diluted 1:1 
in PBS was layered  onto identical gradients,  and the position of 
sCR1 was determined.  (b) Vesicles released  from E during ATP 
depletion are enriched in E-CR1 (18). Such E-vesicles were obtained 
as reported previously (18) and analyzed by SDGU. (c) The posi- 
tion of IgM in the gradient was determined by using radiolabeled 
monoclonal IgM. In another series of experiments, 0.5% (final con- 
1 Abbreviations used in this paper: E-CtL1, CR1 of erythrocytes; HBsAg, 
hepatitis B surface antigen; sCR1, soluble CR1 of plasma; SDGU, sucrose 
density gradient ultracentrifugation;  uCR1,  CR1 of urine. 
centration) SDS or 0.5% Triton was added to the samples of con- 
centrated urine, E-vesicles, and serum before ultracentrifugation. 
150 ml fresh centrifuged urine supplemented with 30 mg of BSA 
(Sigma Chemical Co., St. Louis,  MO) was concentrated 30-fold 
using the PM30 Amicon membrane. The concentrated urine (5 
ml) was applied to a column (Sephacryl-300,  2.5  x  90 cm, vol., 
600 ml; Pharmacia,  Uppsala, Sweden)  equilibrated with PBS at 
a flow rate of 50 ml/h.  Fractions of 3 ml were collected and as- 
sessed for the presence of CR1.  Similar analyses were performed 
with undiluted  serum (5  ml). 
In the Sephacryl-300 elution profiles of concentrated urine, the 
four  fractions containing  the  highest  CR1  concentration  were 
pooled and concentrated with a Centricon 10 (Amicon, Beverly, 
MA) previously coated with PBS-BSA  1%  to a final vol of 150 
/A. The phospholipid and total cholesterol content of these pooled 
concentrates of partially purified uCR1 was analyzed with com- 
mercially available enzyme assays (respectively,  Phospholipids B, 
Wako  Chemicals  GmbH,  Neuss,  Germany;  and  CHOD-PAP, 
Boehringer Mannheim, Germany) (19). The total protein content 
was determined by the method of Lowry et al.  (20). 
Electron Microscopy of lmmunopurified uCR1.  50 #1 of magnetic 
particles covalently coated with goat anti-mouse Ab (Advanced 
Magnetics Inc., Cambridge, MA) was incubated with 20 #g of 
anti-CR1 mAb 3D9,  or control anticomplement factor D  mAb 
72-96-25  (21), in a final vol of 250 #1 PBS-BSA 0.1%  for 5 h at 
4~  After three washes with PBS, the mAb-coated particles were 
incubated with samples of 150 #1 of pooled concentrate of the par- 
tially purified uCR1 (containing 100 ng of CR1 antigen as deter- 
mined in the ELISA) for 2 h at 4~  After three washes,  the mag- 
netic particles were fixed in 2% glutaraldehyde, dehydrated, and 
processed for electron microscopy as previously described (22). Thin 
sections were examined in a Philips EM301 electron microscope. 
Analysis  of uCRI  by Immunoblotting.  Pooled concentrates  of 
uCR1 partially purified by Sephacryl-300 or the pellet of urine which 
had been ultracentrifuged for 60 min at 200,000 g were electro- 
phoresed under nonreducing conditions on a 4% SDS-PAGE gel. 
Proteins were blotted onto nitrocellulose membranes, blots were 
incubated  overnight  with  2  x  105  cpm/ml  of 125I-3D9 mAb, 
washed,  and autoradiographed, uCR1 was compared to E-CR1, 
PMN-CR1, and sCR.1. Erythrocyte membranes and E-vesicles were 
prepared as previously described (18). PMN membranes were ob- 
tained as follows:  fresh PMN were purified from 30 ml of periph- 
eral blood using a Ficoll-Hypaque gradient (Pharmacia) and hypo- 
tonic lysis (23).  The cells (5  x  106/ml) were resuspended in 0.25 
M glucose in the presence of 0.5 mM DFP, 1 mM PMSF, and 10 
mM EDTA, and were subsequently homogenized with a device 
(ball homogenizer) as described by Balch et al.  (24).  Briefly,  the 
cell suspension was forced repeatedly (via attached syringes) through 
the device. Approximately 8-12 passes were required to break most 
of the cells. The crude homogenate was centrifuged at 600 g for 
10 min at 4~  to remove residual cells and nuclei.  The supernatant 
was ultracentrifuged at 27,000 g for 7 min at 4~  to remove lyso- 
somes and mitochondria. Finally the supernatant (containing PMN 
membranes) was ultracentrifuged at 200,000 g for I h at 4~  The 
pellet was resuspended in a 100-200 #1 vol of PBS containing 0.5 
mM DFP,  1 mM PMSF,  and 10 mM EDTA. sCR1 was purified 
from serum by immunoaffinity on 3D9 mAb-Sepharose as previ- 
ously described (15). 
Partially purified uCR1 and E-CR1 solubilized from E or E-vesicle 
membranes were also immunoprecipitated and subsequently ana- 
lyzed by immunoblotting.  In brief,  samples of 100/A of uCR1 
and E-CR1 (containing ,x,100 ng of CR1 antigen as determined 
in the ELISA) were incubated with 3 #g of anti-CR1 mAb 3D9, 
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/zl final vol), for 4 h at room temperature with gentle mixing. The 
CRl-anti-CR1  complexes were precipitated using 100/~1 of pro- 
tein A-Sepharose CL4B (50%, vol/vol) as immunosorbent (Phar- 
macia). After centrifugation at 200 g and three washes in cold PBS, 
the samples were denatured for 20 min at room temperature in 
the absence of reducing agent, and were electrophoresed and re- 
vealed after immunoblotting as described above. 
In other experiments, partially purified uCR1,  E membranes, 
and E-vesicles from the same individual were treated with N-glyco- 
sidase F (Boehringer Mannheim AG, Rotkreuz, Switzerland) in 
0.25 M sodium acetate, 10 mM EDTA, 0.1% SDS, and 0.6% Triton, 
for 16 h at 37~  with enzyme concentrations at 10 U/ml. These 
samples were subsequently analyzed by immunoblotting as described 
above. 
IC Adherence Assays.  Radioiodinated hepatitis B surface antigen 
(HBsAg)/Ab complexes were prepared as previously reported (25). 
C3b-coated HBsAg/Ab complexes were formed by a 15-rain incuba- 
tion of HBsAg/Ab with normal human serum at 37~  followed 
by SDGU to partially purify the complexes. The binding of C3b- 
coated HBsAg/Ab complexes (15/xl =  5 ng Ag) to partially purified 
uCR1 or to CR1 of E-vesicles obtained from the same individual 
(bearing the A allele of CR1) was measured as follows:  15/xl of 
complexes was added to 185 #1 of a uCR1 or E-vesicle suspension 
(in PBS-BSA 0.1% buffer) containing fixed number of CR1 mole- 
cules (1.6 x  109 CR1). The suspensions were incubated for 30 min 
at 37~  Bound C3b-coated HBsAg/Ab complexes were separated 
from unbound material through oil by centrifugation at 40,000 g. 
Control experiments showed that C3b-coated HBsAg/Ab complexes 
were retained on the water/oil interface, and were pelleted only 
when bound to uCR1 or to CR1 of E-vesicles. Similar assays were 
performed to assess the specificity of the binding the C3b-coated 
HBsAg/Ab complexes to uCR1 or to E-vesicles: uCR1 and E-vesicles 
were preincubated for 30 min at 37~  with an excess of anti-C1L1 
mAb 3D9 (10,000-fold excess of 3D9 over CR1) before incubation 
with C3b-coated HBsAg/Ab complexes. As a nonspecific control, 
the anticomplement factor D  mAb was used (21). All measure- 
ments were done in duplicate. 
Urine and Blood Samples  from Normal Individuals and Patients.  In 
12 normal individuals,  24-h urine collections were used to define 
the mean uCR1 daily excretion rate, and the ratio uCR1/u-creatinine 
was calculated.  In two individuals,  the uCR1 and u-creatine were 
determined separately in the urine of each micturition over 24 h. 
Blood samples were collected to measure sCR1 and E-CR1. Similar 
measurements were performed in different groups of patients: (a) 
9 patients with SLE satisfying >t 4 of the 1982 revised criteria of 
the American Rheumatism Association; (b) 10 patients with various 
renal diseases on renal biopsy including minimal change disease 
(2), membranous nephropathy (2), focal sclerosis (3), and diabetic 
nephropathy (3).  In addition, urine and blood samples were col- 
lected in 11 patients who had undergone renal transplantation (at 
least 6 mo before the study) to compare their respective uCR1 and 
E-CtL1 phenotypes. Similar analysis were performed in four patients 
who had undergone bone marrow transplantation (at least 6 mo 
before the study) as a treatment for hematological malignancies. 
Statistical Analysis.  Data were compared by using the Student's 
t test or the nonparametric Mann-Whitney test. Correlations were 
studied by regression analysis. 
Results 
Detection of CR1 Antigen in Urine.  In the human kidney, 
visceral epithelial cells of glomeruli (podocytes) express CR1 
(4). The possibility that such cells release CR1 into the urine 
was investigated. Fresh urinary samples were centrifuged at 
1,500 g  to remove cell debris and assayed for CR1  antigen 
by a sandwich ELISA using two mAb. The specificity of this 
ELISA has been established previously for soluble CR1  in 
plasma (sCR1) (15). CR1 was detected in urine (uCR1), and 
there was a dose-response relationship between the volume 
of urine (between  10 and  50/zl)  and  the amount  of CR1 
antigen detected. To confirm the specificity of the ELISA signal 
in urinary samples, fresh urine was depleted of uCR1 by im- 
munoadsorption  chromatography  using  Sepharose-bound 
mAb. Such uCRl-depleted urine was negative in the ELISA 
(data not shown). In the first normal urines (n  =  12) tested, 
the concentration of uCR1  varied from 0.96 to 4.2 ng/ml 
(mean  =  2.38  _+  1.29 ng/ml) corresponding to an approxi- 
mately 10-fold lesser concentration than sCR1 in plasma. To 
examine the effects of different storage conditions on the con- 
centration of uCR1, urine samples from three normal indi- 
viduals (previously centrifuged at 1,500 g  for 15 min) were 
stored for 2 h  at various temperatures or frozen at  -80~ 
No significant differences in uCR1 concentrations were ob- 
served between 18 and 37~  however, the storage of urine 
at  4~  was  responsible for a  significant drop of uCR1  in 
one urine sample,  from 2.1 to 0.6 ng/ml,  which may have 
been due to the formation of urate crystals at 4~  in this 
sample. Freezing urine at  -  80~  did not modify uCR1 con- 
centrations.  Thus, all urine samples were left at room tem- 
perature before being frozen at  -80~ 
In 12 normal individuals, 24-h urine collections were per- 
formed (Table 1).  The mean daily excretion rate of uCR1 
was 3.12 _+  1.15 (1 SD)/~g/24 h (range, 1.39 -  5.22/~g/24 h). 
In these samples, the ratio of a uCR1/u-creatinine was 0.23 
_+ 0.08 (1 SD)/~g/mmol. In two individuals in whom uCR1 
Table  1.  Daily Excretion Rate of uCR1  in Normal Individuals 
Subject  uCtL1  U-creatinine  uCR1/creatinine ratio 
~g/24  h)  (mmol/24  h)  Q.tg/mmol) 
1  4.22  12.5  0.34 
2  3.08  9.2  0.33 
3  1.39  8.4  0.17 
4  2.66  12.3  0.22 
5  3.65  13.2  0.28 
6  1.85  11.9  0.16 
7  2.68  15.5  0.17 
8  5.22  14.8  0.35 
9  4.26  18.6  0.23 
10  1.78  14.5  0.12 
11  2.83  18.1  0.16 
12  3.87  21.3  0.18 
Mean  3.12  _+  1.15  14.2  +  3.8  0.23  _+ 0.08 
(_+ I SD) 
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Urine  samples* 
1  2  3  E-vesicles* Serums 
Before centrifugation  3.71  3.05  2.10  20.1  35.0 
After 60 rain centrifugation 
at 50,000 g  1.47  1.07  0.39  0  ND 
at 200,000 g  0  0  0  ND  34.8 
* Fresh urine samples from three different normal donors. 
E-vesicle suspensions in PBS. 
S Fresh serum from a normal donor. 
concentrations  were determined  separately in the urine ob- 
tained from each micturition during 24 h, there was a direct 
correlation between the uCR1 and the creatinine concentra- 
tions  (r  =  0.89  and  r  =  0.82,  in  both: p  <  0.05),  corre- 
sponding to mean uCR1/u-creatinine ratios of 0.25 and 0.21. 
It is noteworthy that no correlation was found between uCR1 
elimination and sCR1 or E-CR1 numbers (data not shown). 
uCRI  Is Membrane Bound.  The next  step was to deter- 
mine whether uCR1 was free, similarly to sCR1 in plasma, 
or attached to membrane fragments. It has been shown that 
E which  have been attacked by complement  or depleted of 
ATP release small fragments of cell membranes in the form 
of vesicles (18, 26). These vesicles contain several membrane 
proteins including CR1 (E-CR1).  After ultracentrifugation 
for 1 h at 50,000 g, the CRI bound to E-vesicles is pelleted, 
whereas  sCR1  from plasma remains  in  solution  even after 
centrifugation at 200,000 g (15,  18,  and Table 2). The con- 
centration  of a uCR1  was reduced  in the supernatant  after 
centrifugation  at 50,000 g  for 1 h,  and no uCR1  remained 
0.2. 
0.0. 
1.5. 
9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24 
Vesicles 
2  3  4  5  6  7 
Table  2.  Effect  of Uhracentrifugation on CRI  Concentration in 
Urine (uCRI),  E-vesicles (E-CR1), and Serum (sCR1) 
Urine 
1.2. 
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"-~  0.6. 
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Figure  1.  SDGU of E-vesicles  derived from ATP-depleted  human E (top) 
and urine from a normal individual (bottom). Fractions were assayed for 
CR1  antigen. Samples of E-vesicles or urine (0) were ultracentrifuged 
as described in Materials and Methods. Similar samples were treated with 
a 0.5% solution of SDS (O) or Triton (I-q, bottom)  before application onto 
the gradients. The bottom of the gradient is on the left. (Arrow) Position 
of radiolabeled IgM. 
in solution after 200,000 g  (Table 2). The u-CR1 was recov- 
ered in the pellet that had been resuspended in buffer (data 
not  shown). 
Urine samples were then subjected to ultracentrifugation 
on sucrose density gradients and compared with sCR1 from 
plasma and to E-vesicle-bound CR1 obtained after ATP deple- 
tion of human E  (Fig.  1).  sCR1 was found in late fractions 
Table  3.  Proteins  and Lipids Associated with Partially Purified uCRI from Four Normal Subjects 
Preparation 
(CK1 phenotype)  uCR1  Protein  Cholesterol  Phospholipids 
Cholesterol/ 
phospholipids 
ratio 
gg/ml 
1 AA  0.737  1,170  191.1  144.0 
2  AA  0.199  820  223.0  138.5 
3  BB  0.053  800  116.8  77.7 
4 AA* 
(1)  0.540  1,100  172.6  119.6 
(2)  0.170  312  54.8  38.6 
1.33 
1.61 
1.50 
1.44 
1.42 
* Done twice at 1-mo interval. 
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shown), whereas uCR1 and E-vesicle-bound CR1 were found 
in  the initial  fractions,  with uCR1 being recovered over a 
wider range of fractions. However, when uCR1 or E-vesicle 
were incubated with two types of detergents (0.5% SDS or 
0.5% Triton) in order to dissolve membranes before ultracen- 
trifugation,  the  CR1  antigen  was displaced  and  recovered 
in the same fractions as sCR1. The difference in size between 
uCR1 and sCR1 was also demonstrated  after gel filtration 
chromatography  on Sephacryl-300, i.e.,  uCR1 antigen was 
present in the initial  fractions (>t106 Mr, whereas sCR1 from 
plasma was recovered as expected between IgM and IgG (data 
not  shown). 
To analyze whether uCR1 was found in fractions containing 
cell membranes, the four fractions of the Sephacryl-300 chro- 
matography containing  the highest concentration  of uCR1 
antigen were pooled and concentrated, and lipid contents were 
determined.  Four different urine samples were analyzed and 
in aU there was an almost fixed ratio of cholesterol to phos- 
pholipids (mean  =  1.45) (Table 3). uCR.1 from one individual 
Figure 2.  Electron microscopy  of urinary vesicles purified by immunoaffinity with anti-CR1 coated magnetic particles. Representative examples 
of vesicles fixed onto the magnetic particles are shown. 
893  Pascual  et al. was purified twice at  l-too intervals.  In both samples,  the 
relative  concentrations of uCR1,  total proteins,  and lipids 
were very similar. 
However, this analysis only indicated the copurification of 
uCR1 with membranes.  A direct evidence  for the associa- 
tion between uCR1 and membranes was obtained by ultra- 
structural studies, uCR1 partially purified by Sephacryl-300 
was immunopurified with magnetic particles coated with mAb 
against CR1 (3D9), and fixed. By electron microscopy, double 
membrane structures typical of cell membranes were seen at- 
tached to the magnetic particles,  most in the form of vesicles 
of various sizes without any visible cytoplasmic structures 
inside (Fig.  2).  No such vesicles were seen attached to the 
beads in the control experiment performed with a nonrele- 
vant mAb  (anticomplement factor D  mAb). 
Characterization  of uCR1.  The structural characteristics 
of uCR1 were analyzed next. After partial purification by 
Sephacryl-300,  uCR1 was applied to 4% SDS-PAGE under 
nonreducing conditions. The gels were blotted onto nitrocel- 
lulose membranes that were probed with 12sI-3D9 mAb and 
autoradiographed. Two observations were made. First, the 
apparent molecular mass of uCR1 was slightly larger (15 kD) 
than that of E-CR1  (Fig.  3).  Second, the structural poly- 
morphism of E-CR1 was also found for uCR1 (27-30), and 
for the 10 normal individuals tested, the polymorphism of 
uCP,1 was identical to that of E-CR1. These individuals in- 
cluded the AA, AB,  BB, and AD phenotypes. Differences 
in N-glycosylation have shown to account for cell-specific 
molecular weight differences of CR1 between PMN and E 
(31). To assess the possible role of N-linked oligosaccharides 
in the difference in the molecular weights observed for E-CR1 
and uCR1, partially purified uCP,1 and E-CR1 derived from 
solubilized E  membranes  or  E-vesicles  were  treated with 
N-glycosidase F. The size of both uCR1 and E-CR1 was re- 
duced by treatment with N-glycosidase F, however the differ- 
ence in molecular weight was not totally abrogated (Fig. 4). 
This experiment was performed four times, using two different 
donors, and the results repeatedly showed the persistence  of 
Figure 4.  N-glycosidase  F treatment  ofuCR.1  and E-CR.1  from  a normal 
individual  homozygous  for the A allele. Partially  purified  uCR1 (U) and 
E-CR1 from  solubilized  E membranes  (E) and E-vesicles  (~) (see  Materials 
and Methods)  were  treated  with N-glycosidase  F or buffer  alone  (Control). 
After  enzymatic  treatment,  the samples  were  analyzed  by 4% SDS-PAGE 
and immunoblotting. 
a small difference  in molecular weight after N-glycosidase 
F treatment. Thus the variation in apparent molecular weight 
was not entirely due to the presence  of N-linked oligosac- 
charides.  The difference  in size was also seen when uCR1 
and E-CR1 from E were immunoprecipitated with the anti- 
CR1 3D9 mAb before being electrophoresed, i.e., uCR1 ap- 
peared slightly larger than E-CR1 (data not shown). Finally, 
the size of uCR1 was also 15 kD larger than sCR1 purified 
from serum (sCR1) by immunoaffinity on anti-CR1 (3D9) 
mAb-Sepharose  (15) (Fig. 5), and ~5-10 kD larger than CR1 
obtained from solubilized PMN membranes (Fig.  6). 
uCR1 Originates  from the Kidney.  Vesicle-bound uCR1 may 
originate from the kidney podocytes, circulating cells, or the 
soluble form in plasma. We took advantage of the structural 
polymorphism of CR1 to investigate this question. In pa- 
tients who had undergone renal transplantation, a discrepancy 
between the structural alleles of CR1 between E-CR1 and 
uCR1 would indicate that uCR.1 derived from the grafted 
kidney. In 11 patients with transplanted kidneys,  the struc- 
tural alleles ofuCR1 and E-CR1 differed on seven occasions 
(Fig.  7 and Table 4). 
We also analyzed E-CR1 and uCR.1  structural polymor- 
Figure 3.  uCK1  and E-CR1 phenotypes in three normal individuals 
bearing different  CR1 alleles. Respectively,  lanes: (I) the AA (190 kD), 
(2) the BB (220 kD), and (3) the AD (190 and 250 kD) alleles. Samples 
of partially  purified  uCR1 and E-CR1 from  solubilized  E membranes  were 
analyzed by 4% SDS-PAGE and immunoblotting  with 125I-3D9 mAb. 
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Figure 5.  Comparison  of  uCR1 
and sCR1 from a normal indi- 
vidual homozygous  for the A al- 
lele. sCR1  was purified  from  serum 
by immunoadsorption.  The sam- 
ples were analyzed  by 4% SDS- 
PAGE and immunoblotting. Figure  6.  Comparison  of  PMN- 
CR1  (PMN), E-CR1  (E)  and 
uCIL1 (U) from a single donor 
homozygous  for the A allele.  Solu- 
bilized PMN and E membranes 
were  prepared as  described in 
Materials and Methods. The sam- 
ples were analyzed by 4% SDS- 
PAGE and immunoblotting. 
phism in the reverse situation, i.e., after bone marrow trans- 
plantation. Four patients were studied; the donor was always 
a family relative. In one patient a discordance between E-CR1 
and uCR1 was found (AA and AB respectively), and as ex- 
pected the donor (brother) was AA (data not shown). Thus 
the E-CR1 allele (AA) had been acquired after bone marrow 
transplantation. 
uCR1 Mediates Immune Adherence.  The capacity of uCR.1 
to bind C3b was analyzed using radioiodinated C3b-coated 
HBs Ag/Ab immune complexes as described in Materials and 
Methods.  uCRl-containing  vesicles were able  to bind im- 
mune complexes (Fig. 8). The binding was specific, since im- 
mune complexes were not pelleted in the control experiments 
performed either in the absence of uCR1 or in the presence 
of uCR1  and  a  10,000-fold excess of anti-CR1  3D9  mAb 
(which blocks the C3b-binding sites of CR1). Although the 
immune  adherence increased  directly with  the  amount  of 
uCR1 used, the efhciency of the binding was lower than that 
of E-CR1  since,  at an equal CR,1 concentration,  E-CIL1 of 
E-vesicles bound more immune complexes than uCR1 (Fig. 8). 
Levels of uCR1  in Patients with SLE and Various Renal Dis- 
eases.  Acquired loss of renal podocyte CR1 has been described 
in several diseases in which glomeruli are severely damaged, 
such as in proliferative lupus nephritis,  focal hyalinosis, and 
crescentic nephritis (4, 7,  10-13).  In a preliminary study of 
nine patients with SLE, we found a low uCR1 in the three 
patients with histological evidence of severe proliferative lupus 
nephritis  (Table 5).  There was  no correlation between the 
activity of the disease or E-CR1  numbers  and uCR1.  Out 
of 10 patients with various renal diseases, 3 had low uCR1, 
all of whom had focal sclerosis (Table 6). There was no corre- 
lation  between uCR1  and  proteinuria  in  these  patients. 
Discussion 
The major conclusion of this study is that a distinct form 
of CR1  (uCR1) is present in human urine. Its unique char- 
Table  4.  Analysis  of  E-CRI and uCRI Phenotypes in Patients Who 
Underwent Renal  Transplantation 
Subject  E-CR1  uCR1 
1  AB  A 
2  A  AB 
3  AB  AD 
4  A  A 
5  A  A 
6  AB  A 
7  A  AB 
8  A  A 
9  A  A 
10  A  AB 
11  AB  A 
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Figure 7.  Discordance  between  uCR1 
(U) and E-CR1 (E) phenotypes in a pa- 
tient who underwent renal transplanta- 
tion. The samples were analyzed  by 4% 
SDS-PAGE and immunoblotting.  This 
patient had E-CR1 of the A phenotype 
(corresponding  genotype  AA), and uCR1 
of the AB phenotype (corresponding to 
the genotype of the kidney donor). 
Figure  8.  Adherence  of C3b-coated  HBsAg/Ab immune complexes  to 
CR1 on urinary vesicles (uCRI) or E-vesicles  (/7). (A) There was a dose- 
dependent increase in the adherence  of immune complexes  to both types 
of vesicles. (B) The specificity  of the binding was shown by incubating 
immune complexes  alone (control, Co), with partially purified uCRI in 
the presence of mAb blocking the binding sites of C3b on CIL1 (3D9) 
or a control mAb (mAbCo), or with E-vesicles.  The amount of E-vesicles 
used was adjusted to offer the same amount of CR1 than uCR1 (4 ng). 
The percentage  of  binding was determined  after  centrlfugation  through oil. 
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Patient  E-CR1  Ratio 
Age/sex  Main clinical manifestations  (number/E)  sCR1  uCR1  u-Creatine  p-Creatine  uCR1/u-creatine 
1 26/F 
2 38/F 
3 18/F 
4 43/F 
5 44/F 
6 33/F 
7 47/F 
8 21/F 
9 20/F 
(ng/ml)  (ng/ml)  (mmol/liter)  ~mol/liter) 
Arthritis,  serositis  87  36.9  4.80  7.8  74  0.61 
Arthralgia,  serositis  156  43.6  2.30  3.3  60  0.69 
Arthritis,  normal  renal biopsy  539  44.5  3.65  25  ND  0.15 
Nephritis  (II)**, arthralgia  375  38.7  1.10  3.7  90  0.29 
Nephritis  (II)  461  57.2  1.40  6.6  ND  0.21 
Nephritis  (II),  hemolytic  anemia  219  28.6  5.35  11.1  80  0.48 
Nephritis  (IV)~, CNS  damage  356  25.8  0.31  5.8  80  0.05 
Nephritis  (IV),  CNS damage  181  25.1  <0.2  2.7  192  <0.07 
Nephritis  (IV)~  295  22.0  0.32  7.5  259  0.04 
* Renal biopsy  performed  in patients 3-9. World Health Organization classification  of lupus nephritis: II, mesangial hypercellularity  and/or deposits; 
IV, diffuse proliferative  glomerulonephritis. 
Patients in whom the nephritis was in clinical remission at the time of the urine collection. 
CNS, central nervous system. 
acteristics  suggest that uCR1 is not derived from either CR1 
orE or PMN, or from sCR1 found in plasma, but originates 
from the renal podocytes. 
The uCR1 was initially detected in urine using the sand- 
wich ELISA previously shown to be sensitive and specific for 
sCR1 in plasma (15).  We demonstrated that the assay was 
reliable for detecting CR1 in urine as well. The concentra- 
tion ofuCR1 was "2-3 ng/ml, i.e., 10-fold lower than sCR1 
in plasma.  Because of its high molecular weight,  sCR1  is 
unlikely to be filtered through the glomerulus to any significant 
amount,  suggesting another origin for uCR1. 
By carefully examining its properties, we first showed that 
uCR1 was not, strictly speaking, soluble since it was pelleted 
after ultracentrifugation whereas under similar conditions 
sCR1 remains soluble (15). This strongly suggested that uCR1 
was bound to cell membrane fragments. Indeed, when ana- 
lyzed by SDGU, uCR1 was found to sediment in the initial 
fractions of the gradient  (>19 S), well above the fractions 
containing sCR1  from plasma,  and comigrated with CR1 
present on E-vesicles derived from ATP-depleted E. E-vesicles 
have been shown to constitute a population of spheres with 
a diameter of "200 nm (26), and contain several membrane 
proteins including CR1 (18, 32). After preincubation with 
detergents (Triton or SDS), both uCR1 and CR1 of E-vesicles 
sedimented similarly to sCR1,  as would be expected from 
proteins associated  with lipid membranes. More direct evi- 
dence for the membrane association of uCR1 was provided 
by electron microscopy of affinity-purified uCR1. The beads 
Table 6.  uCR1  in Patients with Various Renal Diseases 
Patient  E-CR1  Ratio 
Age/sex  Disease  (number/E)  sCR1  uCR1  u-Creatine  p-Creatine  uCR1/u-creatine 
(ng/ml)  (ng/ml)  (retool/liter)  ~mol/liter) 
1 80/M  MCD with NS  612  33.7  14.5  19.3  98  0.75 
2 49/M  MCD with NS  480  39.8  2.32  14.7  95  0.15 
3 75/F  MN with proteinuria  615  56.5  3.50  9.7  100  0.36 
4 21/F  MN with NS  635  17.4  1.16  2.2  65  0.52 
5 67/F  DN with NS  395  33.1  1.53  4.7  283  0.32 
6 49/F  DN with proteinuria  272  107  1.30  9.6  188  0.14 
7 50/F  DN with proteinuria  309  64.5  1.10  3.7  184  0.30 
8 34/F  FS with NS  313  59.7  0.13  4.7  179  0.03 
9 76/F  FS with NS  480  60.1  0.20  2.8  527  0.07 
10 28/F  FS with NS  ND  43.6  0.23  4.7  175  0.05 
DN, diabetic nephropathy; FS, focal sclerosis; MCD, minimal change disease; MN, membranous nephropathy; NS, nephrotic syndrome. 
896  Identification  of Membrane-bound CR1 in Human Urine coated with anti-CR1 mAb bore on their surface small vesicles 
of varying sizes presenting double membranes typical of cell 
membranes. Most of these vesicles looked empty and so it 
was not possible  to distinguish between vesicles released by 
cells and fragments of cell membranes taking a vesicular con- 
formation upon preparation for the electron microscopy. An 
additional evidence for the membrane association of uCR1 
was provided by the analysis of cholesterol to phospholipid 
ratio of the fractions containing uCR1 after Sephacryl-300 
gel filtration. This ratio (1.45) was higher than expected for 
cell membranes (most often ~1 [33,  34]) and it might cor- 
respond to the specific composition of the vesicles' membrane. 
Several reports (35-37) have indicated that the release of vesicles 
by cells is due to the properties of certain phospholipids or 
sphingolipids of membranes that are specifically incorporated 
(or not) into the forming bud on the cell membrane. For 
instance, protasomes which are small vesicles (mean diameter, 
150 nm) released by epithelial cells of the prostate into the 
seminal fluid, have a cholesterol/phospholipid ratio of `"2 
(38,  39). 
When assessed by SDS-PAGE under nonreducing condi- 
tions, the apparent molecular mass of uCR1 was slightly larger 
than that of sCR1,  E-CR1  (both 15 kD), and PMN-CR1 
(5-10 kD). Differences in N-glycosylations have been shown 
to account for cell-specific  molecular weight differences of 
CR1 between PMN and E (31). After incubation with N-gly- 
cosidase-F, which is known to remove all N-linked oligosac- 
charides, uCR1 lost "30 kD,  similarly to E-CR1,  so that 
the small difference in size persisted. Thus, the higher mo- 
lecular weight of uCR1 could not be attributed only to the 
presence of N-linked oligosaccharides. Whether other types 
of glycosylations may explain this difference in size remains 
possible.  However it is worth emphasizing that Lublin et al. 
(31) could not find any evidence for O-glycosylations in lym- 
phoblastoid cell lines.  The larger size of uCR1 may be due 
to a difference in the amino acid sequence. However this seems 
unlikely since no alternate splicing has been reported for CR1 
(2). Another possibility is that urine is responsible for some 
subtle modifications in the properties and/or  structure of 
uCR1. 
The structural polymorphism of CR1 was conserved for 
uCR1,  thus it was possible to define after SDS-PAGE  and 
immunoblotting, the A, B, and D alleles for uCR1, similarly 
to E-CR1. As expected in all normal individuals tested, the 
structural polymorphism was identical for uCR1 and E-CR1. 
This observation allowed us to define whether the membranes 
bearing uCR1 stemmed from the renal podocytes or from 
blood-derived cells which are found in normal urine. In pa- 
tients who had undergone renal transplantation,  there was 
a frequent discrepancy in the structural polymorphism between 
uCR1 and E-CR1 which suggested very strongly that uCR1 
was of donor origin. That the kidney is the origin of uCR1 
was further indicated by analyzing the reverse situation, i.e., 
a patient who had undergone bone marrow transplantation 
and in whom the structural polymorphism of E-CR1 was 
similar to that of the donor of the hematopoietic cells, but 
different from its uCR1.  Since only podocytes are known 
to express CR1 in the kidney, the logical conclusion was that 
membranes (vesicles)  bearing uCR1 originated from podocytes. 
Many circulating and other cells have been shown to release 
vesicles by budding at the time of complement attack or under 
other conditions (40-46). Thus, the release of vesicles by podo- 
cytes would by no means be unique. Whether CR1 on the 
surface of these vesicles plays a biological role remains un- 
defined. The presence of "immune adherence" receptors on 
podocytes, i.e., in a bodily compartment exposed exclusively 
to primitive urine, has intrigued many investigators (4-13). 
The most likely functions of CR1 on podocytes are the trans- 
port of C3b-coated immune complexes into urine and the 
inactivation of C3b in pathological circumstances in which 
plasma proteins come into contact with podocytes. To sup- 
port  this  hypothesis was  the observation  that  uCR1  was 
capable of mediating immune adherence of C3b-coated im- 
mune complexes. However, at an equal amount of CR1, im- 
mune adherence was much lower than for E-CR1. This differ- 
ence may be explained by the unique clustered distribution 
of CR1 on E which favors immune adherence (47, 48), or 
by a loss of function of uCR1 by its exposure to urine. How- 
ever, it is worth emphasizing that the uCR1, being mem- 
brane bound, is more efficient at reacting with C3b-coated 
immune complexes than recombinant sCR1 (Pascual, M., S. 
Sadallah,  and J.-A.  Schifferli,  unpublished  observations). 
Similar observations  have been made for another complement 
inhibitor. Decay accelerating factor on protasomes of seminal 
fluid is a more potent inhibitor than its soluble urinary coun- 
terpart (49). 
The continuous vesiculation phenomenon might contribute 
to the elimination not only of C3b-coated immune complexes, 
but also of the membrane attack complex of complement. 
In an experimental rat model of Heymann nephritis, it has 
been shown that the C5b-C9 complex is transported across 
podocytes by multivesicular bodies that release small vesicles 
coated with C5b-C9  into  the urinary space  (50).  Similar 
vesides were recovered in rat urine. C5b-C9 has been found 
in the urine of patients suffering from membranous nephritis 
(51, 52). Whether such C5b-C9 is bound to vesicles similar 
or identical to CRl-bearing  vesicles  has not yet been de- 
termined. 
The release into the urine of vesicle-bound CR1 from the 
podocytes may provide us, for the first time, with a specific 
marker of podocyte injury in various diseases. In the normal 
individuals tested, the release of uCR1 appeared to be constant 
over time, correlating with the elimination of creatinine. In 
some glomerular diseases, CR1 are known to be lost on podo- 
cytes. In particular, CR1 expression is markedly reduced in 
severe lupus nephritis and focal sclerosis (4).  In the few pa- 
tients with these diseases studied here, several had very low 
excretion of uCR1. No immunohistochemistry analysis has 
been performed in these patients to demonstrate a concomi- 
tant lack of CR1 on glomerular podocytes in the renal biop- 
sies. Studies are now required to assess whether the suggested 
correlation between uCR1 and CR1 expression on podocytes 
is clinically useful, and whether uCR1 is an indicator of the 
severity of glomerular lesions in specific nephropathies. 
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